In this study, we show that PRMT5 inhibition suppresses HR repair of glioblastoma, leading to increased TMZ-induced DNA damage, and enhances the antitumor efficacy in both in vitro and in vivo glioblastoma tumor models. Here, PRMT5 is linked to neoplasm.